SynCo Bio Partners enters the Japanese market as it signs its first agreement with a Japanese pharmaceutical company

SynCo Bio Partners enters the Japanese market as it signs its first agreement with a Japanese pharmaceutical company

September 1, 2009 - Amsterdam, The Netherlands SynCo Bio Partners B.V., the expert in long term GMP contract manufacturing of biopharmaceuticals announced today that it has expanded its business into a new geographical market, with the signing of a contract to manufacture a live biotherapeutic for an emerging Japanese pharmaceutical company. 

The undisclosed company's product is an innovative live biotherapeutic based anticancer drug.  The project will first involve a consultancy phase, during which SynCo will assist the client with in-house process development.  The developed process will then be transferred to SynCo's Amsterdam facility and scaled-up, prior to GMP manufacture for Phase I clinical trials, including fermentation, formulation and aseptic filling.

"We are extremely pleased to be working our first Japanese partner" commented SynCo's CEO, Mr. Pierre Warffemius "this is and exciting project for a leading Japanese business and I look forward to the successful completion of GMP manufacture, in the field of live biotherapeutics.  This contract represents SynCo's entry into the growing Japanese biotherapeutics market and is reflective of our continuing success in a very competitive GMP contract manufacturing market."

SynCo is a specialist in the development of manufacturing processes and GMP production of live biotherapeutics and provides a one-stop-shop for the production of both bulk drug substance and final lyophilized product.  This project is one of a rapidly growing number SynCo is involved with in this field
For more information, please visit  www.syncobiopartners.com or contact:
De Facto Communications
Hilary Latham
+44 207 861 3027      
[email protected]
SynCo Bio Partners B.V.  
Joanne McCudden
+31 6 5534 8074
[email protected]

About SynCo Bio Partners B.V.
SynCo Bio Partners is a GMP-licensed bulk drug substance and final product CMO with clinical and commercial production experience with mammalian and microbial systems. This experience has been acquired by developing new production processes for a number of international clients and producing a wide variety of different vaccines, live bacterial products and recombinant proteins in our state-of-the-art, GMP-licensed facilities since inception in 2000.
Focused solely on biopharmaceuticals, SynCo Bio Partners acts as a strategic, long-term partner delivering product on time to the highest quality standards.  SynCo ‘s team are committed to exceeding customer expectations  taking a truly collaborative approach to manufacturing.
www.syncobiopartners.com

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.